Bio-Rad Laboratories Inc Class A BIO

Morningstar Rating
$296.11 −1.17 (0.39%)
View Full Chart

Company Report

Bio-Rad's Timing for Revenue Growth Recovery Remains Uncertain

Bio-Rad develops products and solutions for the life sciences research and clinical diagnostic markets and enjoys niche market leadership in diagnostic quality controls, antigens, and digital polymerase chain reaction, or dPCR, molecular testing. Bio-Rad’s business relies on the razor-and-blade model typically seen in the diagnostic market, and consumable reagents account for about 70% of total sales, with these reagents often sold at a higher margin than their associated equipment and instruments.

Price vs Fair Value

BIO is trading at a LOCK|B>#s^@P premium.
Price
$296.11
Fair Value
>%c
Uncertainty
LOCK|#m
1-Star Price
j%%
5-Star Price
qFT
Economic Moat
LOCK|tzM
Capital Allocation
LOCK|ZB<rWm

Bulls Say, Bears Say

Bulls

Bio-Rad is a leader in niche areas including quality controls, antigens, and digital PCR, and it has a strong razor-and-blade model in clinical diagnostics.

Bears

Bio-Rad’s life science business currently faces a challenging environment due to funding cuts for US life sciences research and the potential for a weakening biotech funding environment.

News

Trading Information

Previous Close Price
$297.28
Day Range
$295.96302.16
52-Week Range
$236.73343.12
Bid/Ask
$260.00 / $300.00
Shares Outstanding
26.76M
Market Cap
$7.92B
Volume/Avg
204,531 / 376,924

Key Statistics

Price/Earnings (Normalized)
31.55
Price/Sales
3.05
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield
3.04%

Company Profile

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Small Value
Total Number of Employees
7,450

Competitors

Valuation

Metric
BIO
SRT3
TMO
Price/Earnings (Normalized)
31.5573.5422.31
Price/Book Value
1.155.883.70
Price/Sales
3.054.514.30
Price/Cash Flow
17.5722.6219.96
Price/Earnings
BIO
SRT3
TMO

Financial Strength

Metric
BIO
SRT3
TMO
Quick Ratio
2.170.460.97
Current Ratio
3.210.911.53
Interest Coverage
3.883.245.35
Quick Ratio
BIO
SRT3
TMO

Profitability

Metric
BIO
SRT3
TMO
Return on Assets (Normalized)
2.51%2.61%8.27%
Return on Equity (Normalized)
3.59%9.56%17.01%
Return on Invested Capital (Normalized)
2.71%4.49%10.28%
Return on Assets
BIO
SRT3
TMO

Medical Devices Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Abbott Laboratories
ABT
LOCK|!>r#F^LOCK|!>D<q$164B
Stryker Corp
SYK
LOCK|X?@^hF$yLOCK|#<$126B
Medtronic PLC
MDT
LOCK|ZVqH<JLOCK|^zgpX$107B
Boston Scientific Corp
BSX
LOCK|?rCP@GJLOCK|tRG?$67B
Edwards Lifesciences Corp
EW
LOCK|hD?lh?XLOCK|$Q<@>$53B
GE HealthCare Technologies Inc Common Stock
GEHC
LOCK|GkPK%dLOCK|<l$$29B
DexCom Inc
DXCM
LOCK|##q@FG%LOCK|c?#%^$29B
Koninklijke Philips NV ADR
PHG
LOCK|#jLOCK|^#$27B
Steris PLC
STE
LOCK|sNSJ<&LOCK|#zXDJ$21B
Zimmer Biomet Holdings Inc
ZBH
LOCK|sd^@SC$&LOCK|QcL$18B

Sponsor Center